Novartis, a Swiss multinational pharmaceutical company based in Basel, completed the acquisition of The Medicines Company, a biopharmaceutical company, for $9.7bn. The price represents a premium of approximately 45% to The Medicines Company’s closing share price of $58.65 on November 18, 2019. “Our company’s singular, relentless focus and the unwavering commitment of our employees have led to this opportunity to unlock the intrinsic value of inclisiran for patients and to maximize value for our shareholders. We are excited that millions of patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia will potentially benefit from this transformational therapy,” Mark Timney, The Medicines Company Chief Executive Officer.